EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs

Nimotuzumab, an anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, has been used extensively in many solid tumors and confers significant survival advantage. The antibody has limited skin toxicity and is generally well tolerated. Similar to other anti-EGFR therapies, patients may...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Roshan, Vishwakarma, Siddharth, Chivukula, Indira V, Basavaraj, Chetana, Melarkode, Ramakrishnan, Montero, Enrique, Nair, Pradip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544456/
https://www.ncbi.nlm.nih.gov/pubmed/23342262
http://dx.doi.org/10.1002/cam4.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544456/
https://www.ncbi.nlm.nih.gov/pubmed/23342262
http://dx.doi.org/10.1002/cam4.21

Ejemplares similares